Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000180 · ClinicalTrials.gov registry record · Phase 1
AIT-082 Phase 1B Study
A Phase 1 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00000180: Completed Phase 1 study, sponsored by National Institute on Aging (NIA).
NCT00000180 is a Phase 1 study that has completed, run by National Institute on Aging (NIA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000180, a Phase 1 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals with neurological deficits. This study was a double-blind placebo-controlled safety study that was designed to study whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks; were tested for side effects and absorption; and underwent a battery of neuropsychological memory tests, including word and number recall tests.
Interventions
- DRUG AIT-082
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
What the finished NCT00000180 record still lists
NCT00000180 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which AIT-082 is the first listed.
NCT00000180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000180 about?
NCT00000180 is a clinical study titled "AIT-082 Phase 1B Study". AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged animals and in animals wit...
What is the current status of trial NCT00000180?
This trial is currently completed. It is a Phase 1 study. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00000180?
The interventions under investigation include: AIT-082 (DRUG).
Who is sponsoring clinical trial NCT00000180?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.